beta
Pfizer, Inc.

Pfizer, Inc.

PFEBATSShares

$23.38

$0.23

0.99%

6 Jun 20:00

$20.92

$31.54

52 weeks low/high

Market sentiment

Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).

Overall assessment

weak bearish sentiment increases

2day with a yield of0.99%

Share of longs and shorts
Long
100.00%
Change to previous day:0.77%
Short
0.00%
Change to previous day:0.00%
IndexBullsBears
Confidence
Support
Cash flows

Momentum

Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.

  • Return/MDD

    -0.44
  • Sentiment

    Bullish
  • Start Date

    05.20.2025
  • Duration

    17
  • Yield

    -0.72%
  • Avg.Yield

    -2.94%
  • Volatility

    2.03%
  • Max MDD

    -1.65%
  • Avg. MDD

    -7.77%
  • Min Price

    RUB 23.04
  • Max Price

    RUB 23.61
Protective stop levels
S/L 5%RUB 22.18
S/L 10%RUB 21.02
S/L 15%RUB 19.85
Day
1.16%0.00%0.00%
Week
25.90%2.04%0.03%
Month
58.18%25.79%8.09%

Technical analysis

  • Trend Class
    Flat and Down
  • Trend Power
    Strong trend
  • Pattern
    Symmetrical triangle
  • EMA-20
    Bullish reversal
    2025-05-23 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.
  • EMA-50
    Bearish reversal
    2025-05-01 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
  • EMA-100
    Bearish reversal
    2025-03-10 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
  • Stochastic
    Bullish weakening
    The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.
  • RSI
    Bullish weakening
    RSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: exit from the overbought zone.
  • MACD
    Bullish
    Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: up-crossing the middle level.
  • Candle pattern type
    Long Legged
    consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
    Date of signal:

Prices and risks

Price
ChangeChange by industryMin.Max.Volume
Yesterday-3.74%2.64%$23.25$23.58547.90M
Week-4.31%3.10%$23.06$23.624.05B
Month-1.38%0.45%$21.97$23.7018.36B
3 Months-15.91%0.82%$20.92$27.2456.54B
6 Months-12.61%16.34%$20.92$27.57100.55B
Year-21.38%0.64%$20.92$31.54187.78B
3 years-58.34%75.95%$20.92$54.93553.45B
5 years-37.51%100.06%$20.92$61.711.10T
All time9.09%81.24%$11.62$61.711.06T
Volatility
PFEBy industry
Yesterday8.76%1.28%
Week3.14%7.29%
Month5.95%10.86%
3 Months9.98%20.88%
6 Months15.22%29.79%
Year24.02%39.37%
3 years42.09%85.40%
5 years57.39%115.71%
All time
Sortino
-0.64
Sharpe
-0.85
Sterling
-0.66
Liquidity index
7.47
Alpha
-0.00081
Beta
0.53
Indicators are given for the year

AI Factors

Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.

Fundamental analysis

Indicators for the last quarter and their dynamics for 5 quarters

Ratios

Valuation
P/E
16.35
Price/Sales
2.07
P/B
1.48
P/FCF
13.36
Debts
D/E
0.65
Efficiency
ROE
8.88
ROA
3.69
ROI
5.39
Net Worth
131.39
Quick Ratio
0.92
Current Ratio
1.17
Other ratios
Net Profit Margin
12.62
Operating Margin
19.51
Gross Margin
71.94
Return on tangible equity
0.00
Revenue
EPS
0.92
EPS Forecast
0.64
Revenue
17.76B
Gross Profit
11.85B
EBITDA
4.14B

Financials

Growth
Net Income
$410.00M
Operating Income
$2.35B
Assets
Total Assets
$213.40B
Cash on Hand
$20.48B
Total share holder equity
$88.50B
Debts
Long Term Debt
$57.41B
Total liabilities
$124.90B

News

About

$132.75B

Capitalization

5.69B

Shares outstanding

Health Care

Sector

Pharmaceuticals

Industry

US7170811035

ISIN

100

Lot size

Dr. Albert Bourla D.V.M., DVM, Ph.D.

CEO

pfizer.com

Website

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.